CLDN2 and breast carcinoma: In agreement with our immunoblotting results, quantitative real-time PCR showed that CLDN2 mRNA levels are increased in both human and mouse breast cancer cells following treatment with pan-SFK inhibitors (1.73 – 3.33 fold induction for Dasatinib; 6.51 – 30.7 fold induction for PP2; Supplementary Figure 1A–1D).